Penumbra, Inc. (PEN) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $318.01 — A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.9/10.
Penumbra designs and sells thrombectomy and embolization medical devices for ischemic stroke, pulmonary embolism, and peripheral vascular disease, generating $1,403.7M in revenue in 2025 (+17.5% YoY). Products are sold through a direct sales organization in the US, Europe,... Read more
Sell if holding. Analyst target reached at $318.01 — A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.9/10. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity 43d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About Penumbra, Inc.
About Penumbra, Inc.
Penumbra generated $1,403.7 million in revenue for the year ended December 31, 2025, up 17.5% from the prior year, driven by its thrombectomy portfolio ($947.9 million) and embolization and access products ($455.7 million). The company, founded in 2004, sells through a direct sales force in the United States, most of Europe, Canada, Australia, and Singapore, and reported operating income of $189.2 million for 2025 following a $115.3 million impairment charge in 2024 related to the exit of its immersive healthcare business.
Penumbra earns revenue primarily through direct hospital sales to specialist physicians — including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists, and vascular surgeons. The thrombectomy business spans peripheral products (Indigo System with computer assisted vacuum thrombectomy technology for pulmonary embolism, deep vein thrombosis, and acute limb ischemia) and neuro products (Penumbra System for ischemic stroke). The company launched Lightning Flash 3.0, Lightning Bolt 12, and Lightning Bolt 6X with TraX in 2025; the THUNDER IDE study evaluating CAVT technology in neurovascular applications completed enrollment in September 2024. Penumbra manufactures substantially all products in-house in California and typically procures certain raw materials and components from a single or limited number of suppliers, creating qualification risk if a supplier change is required. Most notable competitors include Boston Scientific, Medtronic, Stryker (now including Inari Medical), and Terumo.
Show full overview
On January 14, 2026, Penumbra entered an agreement to be acquired by Boston Scientific Corporation at an enterprise value of approximately $14.5 billion, with shareholders to receive $374 per share (73% cash, 27% Boston Scientific stock, subject to proration). Closing is targeted by end of 2026, subject to stockholder approval and antitrust clearances. Until closing, the Merger Agreement restricts Penumbra from entering certain material contracts or making unbudgeted capital expenditures — constraints that could affect pipeline execution if the transaction is delayed, with a $525 million termination fee payable by Penumbra under certain termination scenarios.
See also: Healthcare · Medical Devices
From Penumbra, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Penumbra, Inc.
Latest news
- NEWS Penumbra (PEN) Deep Dive | Q4 2025: Profit Exceeds Views - Dark Pool - Cổng thông tin điện tử tỉnh Lào Cai — Cổng thông tin điện tử tỉnh Lào Cai positive
- NEWS Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A - The Chronicle-Jo — The Chronicle-Journal positive
- NEWS Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A - FinancialContent — FinancialContent positive
- NEWS Here's Why Penumbra (PEN) is a Strong Growth Stock - Yahoo Finance — Yahoo Finance positive
- NEWS Penumbra (PEN) to Release Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
Generated 2026-06-17T08:26:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $318.01 — A.R:R is negative (-0.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.9/10. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $312.48. Score 4.9/10, moderate confidence.
Take-profit target: $323.08 (+1.6% upside). Prior stop was $312.48. Stop-loss: $312.48.
Analyst target reached - limited upside remaining; Weak overall score: 4.9/10; Weak growth.
Penumbra, Inc. trades at a P/E of 73.6 (forward 50.7). TrendMatrix value score: 4.1/10. Verdict: Sell.
21 analysts cover PEN with a consensus score of 3.4/5. Average price target: $363.
What does Penumbra, Inc. do?Penumbra designs and sells thrombectomy and embolization medical devices for ischemic stroke, pulmonary embolism, and...
Penumbra designs and sells thrombectomy and embolization medical devices for ischemic stroke, pulmonary embolism, and peripheral vascular disease, generating $1,403.7M in revenue in 2025 (+17.5% YoY). Products are sold through a direct sales organization in the US, Europe, Canada, Australia, and Singapore. A definitive merger agreement with Boston Scientific at $374/share (~$14.5B enterprise value) was signed January 14, 2026.